Tyr488
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr488  -  RSK2 (human)

Site Information
DVyDDGKyVYVVTEL   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 464203
Associated spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 ) , mutation of modification site ( 2 ) , phospho-antibody ( 2 , 3 ) , western blotting ( 2 , 3 )
Disease tissue studied:
gastric cancer ( 10 ) , leukemia ( 1 , 6 , 11 , 12 ) , acute myelogenous leukemia ( 1 , 6 , 11 , 12 ) , lymphoma ( 13 ) , anaplastic large cell lymphoma ( 13 ) , multiple myeloma ( 7 , 8 )
Relevant cell line - cell type - tissue:
293T (epithelial) ( 2 ) , BaF3 ('B lymphocyte, precursor') [FGFR3 (human)] ( 3 ) , COS (fibroblast) ( 2 ) , HCT116 (intestinal) ( 9 ) , KG-1 (myeloid) ( 1 , 6 , 11 , 12 ) , OPM-1 (B lymphocyte) ( 7 , 8 ) , SNU-16 (gastric) ( 10 ) , SU-DHL1 (T lymphocyte) ( 13 )

Upstream Regulation
Putative in vivo kinases:
Src (human) ( 2 )
Kinases, in vitro:
ERK2 (human) ( 3 ) , FGFR3 (human) ( 3 ) , Fyn (human) ( 2 ) , Src (human) ( 2 )

References 

1

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

2

Kang S, et al. (2008) Epidermal growth factor stimulates RSK2 activation through activation of the MEK/ERK pathway and src-dependent tyrosine phosphorylation of RSK2 at Tyr-529. J Biol Chem 283, 4652-7
18156174   Curated Info

3

Kang S, et al. (2007) FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell 12, 201-14
17785202   Curated Info

4

Gu T (2007) CST Curation Set: 2463; Year: 2007; Biosample/Treatment: cell line, RSK2-6/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

5

Gu T (2007) CST Curation Set: 2464; Year: 2007; Biosample/Treatment: cell line, RSK2-7/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

6

Gu TL, et al. (2006) Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia. Blood 108, 4202-4
16946300   Curated Info

7

Gu T (2006) CST Curation Set: 1725; Year: 2006; Biosample/Treatment: cell line, OPM-1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

8

Gu T (2006) CST Curation Set: 1726; Year: 2006; Biosample/Treatment: cell line, OPM-1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

9

Li Y (2006) CST Curation Set: 1685; Year: 2006; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

10

Guo A (2006) CST Curation Set: 1643; Year: 2006; Biosample/Treatment: cell line, SNU-16/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

11

Gu T (2006) CST Curation Set: 1133; Year: 2006; Biosample/Treatment: cell line, KG-1/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

12

Gu T (2006) CST Curation Set: 1134; Year: 2006; Biosample/Treatment: cell line, KG-1/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

13

Moritz A (2003) CST Curation Set: 167; Year: 2003; Biosample/Treatment: cell line, SU-DHL1/-; Disease: anaplastic large cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info